Choroidal Disease is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Choroidal Disease have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Choroidal Disease compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Choroidal Disease overview
Choroidal dystrophy is an eye disorder that involves a layer of blood vessels called the choroid. Causes include orbital disease (such as retrobulbar tumors), choroidal tumors, ocular hypotony (following significant surgery) and idiopathic, chronic papilloedema and posterior scleritis. Diagnosis is based on clinical examination and ancillary testing. Choroidal imaging, including B-scan ultrasonography and optical coherence tomography. Topical steroids, cycloplegics and mydriatics are used for treating choroidal dystrophy.
For a complete picture of PTSR and LoA scores for drugs in Choroidal Disease, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
